Razavi, Pedram http://orcid.org/0000-0003-4236-0576
Dickler, Maura N.
Shah, Payal D.
Toy, Weiyi
Brown, David N. http://orcid.org/0000-0002-8249-3632
Won, Helen H.
Li, Bob T. http://orcid.org/0000-0001-6661-8733
Shen, Ronglai
Vasan, Neil
Modi, Shanu
Jhaveri, Komal
Caravella, Betty Ann
Patil, Sujata
Selenica, Pier
Zamora, Stephen
Cowan, Aimee M.
Comen, Elizabeth
Singh, Andy
Covey, Anne
Berger, Michael F.
Hudis, Clifford A.
Norton, Larry
Nagy, Rebecca J.
Odegaard, Justin I.
Lanman, Richard B. http://orcid.org/0000-0001-8122-4329
Solit, David B. http://orcid.org/0000-0002-6614-802X
Robson, Mark E.
Lacouture, Mario E.
Brogi, Edi
Reis-Filho, Jorge S. http://orcid.org/0000-0003-2969-3173
Moynahan, Mary Ellen
Scaltriti, Maurizio http://orcid.org/0000-0002-5522-1447
Chandarlapaty, Sarat http://orcid.org/0000-0003-4532-8053
Funding for this research was provided by:
Breast Cancer Alliance
Conquer Cancer Foundation
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA008748, R01 CA234361, R01CA204999)
Article History
Received: 20 August 2019
Accepted: 27 February 2020
First Online: 23 March 2020
Competing interests
: P.R. reports consulting or advisory role for Novartis, AstraZeneca and Foundation Medicine and institutional research support from Illumina and GRAIL; M.N.D. is an employee of Eli Lilly; P.D.S. reports consulting with Tmunity and research funding from AstraZeneca; B.T.L. reports consulting/advisory board for Genentech, ThermoFisher Scientific, Guardant Health, Hengrui Therapeutics, Mersana Therapeutics, Biosceptre Australia and institutional research support from Illumina, GRAIL, Genentech and AstraZeneca; N.V. reports a consulting or advisory role for Novartis; K.J. reports a consulting or advisory role for ADC Therapeutics, AstraZeneca, Jounce Therapeutics, Novartis, Pfizer, Spectrum and Taiho and research funding from ADC Therapeutics (Inst), Clovis Oncology (Inst), Debio (Inst), Genentech (Inst), Novartis (Inst), Novita (Inst), Pfizer (Inst) and other relationships with Jounce Therapeutics, Novartis, Pfizer and Taiho; A.C. reports being an advisory board member for Accurate Medical and a Stockholder for Amgen; L.N. reports honoraria from Advanced Breast Cancer 4 International Consensus Conference, Bluprint Oncology Concepts, Celgene, Context Therapeutics and MCI Breast Cancer Symposium, consulting or advisory roles for Advanced Breast Cancer International Consensus Conference, Bluprint Oncology Concepts, Celgene, Context Therapeutics and MCI Breast Cancer Symposium and travel and accommodations expenses from Advanced Breast Cancer International Consensus Conference, Celgene and MCI Breast Cancer Symposium; A.S., R.J.N., J.I.O. and R.B.L. are employees and stockholders of Guardant Health; M.E.R. reports honoraria from AstraZeneca, consulting or advisory roles for AstraZeneca, McKesson, Merck and Pfizer, research funding from Abbvie (Inst), AstraZeneca (Inst), InVitae (Inst), Medivation (Inst), Myriad Genetics (Inst) and Tesaro (Inst) and travel and accommodations expenses from AstraZeneca; M.E.L. reports serving as a consultant or speaking for Legacy Healthcare Services, Adgero Bio, Amryt, Celldex, Debiopharm, Galderma, Johnson & Johnson, Novocure, Lindi, Merck, Sharp and Dohme Corp, Helsinn Healthcare SA, Janssen Research & Development LLC, Menlo Therapeutics, Novartis, Roche, AbbVie, Boehringer Ingelheim, Allergan, Amgen, E. R. Squibb & Sons, LLC, EMD Serono, AstraZeneca, Genentech, Leo Pharma, Seattle Genetics, Bayer, Manner, SAS, Lutris, Pierre Fabre, Paxman Coolers, Adjucare, Dignitana, Biotechspert, Teva Mexico, Parexel, OnQuality, Novartis, Our Brain Bank and Takeda Millenium; and receiving research funding from Veloce, US Biotest, Berg, BMS, Lutris, Paxman and Novocure; J.S.R.-F. reports personal/consultancy fees from VolitionRx, Page.AI, Goldman Sachs, Grail, Ventana Medical Systems, Roche, Genentech and Invicro; D.B.S. received honoraria and consulted for Pfizer, Loxo, Vivideon, Illumina and Lilly Oncology; M.S. is on the Advisory Board of the Bioscience Institute and Menarini Ricerche, received research funds from Puma Biotechnology, Daiichi Sankyo, Targimmune, Immunomedics and Menarini Ricerche, is a co-founder of Medendi Medical Travel and received honoraria from Menarini Ricerche and ADC; S.C. reports institutional research funding from Novartis, Eli Lilly, Sanofi, Daiichi Sankyo and Genentech and ad hoc consulting for Novartis, Context Therapeutics, Sermonix, Eli Lilly, BMS and Revolution Medicine.